Comparing the current results to its competitors, Ocular Therapeutix Inc reported Revenue increase in the 1 quarter 2026 by 0.81 % year on year. The revenue growth was below Ocular Therapeutix Inc 's competitors' average revenue growth of 9.74 %, achieved in the same quarter.
Ocular Therapeutix Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 2.57 %
Ocular Therapeutix Inc 's Comment on Competition and Industry Peers
The company operates in a competitive environment that includes generic, biosimilar, and branded versions of drugs for ophthalmic diseases. Competitors may file abbreviated new drug applications (ANDAs) or foreign equivalents to market generic versions without clinical development, provided they do not infringe existing patents. The biotechnology and pharmaceutical industries are marked by rapid technological advancements, intense competition, and a focus on proprietary products. Potential competitors encompass large pharmaceutical and biotechnology firms, specialty pharmaceutical and generic drug companies, compounding pharmacies, academic institutions, government agencies, and other public and private research organizations. Several competitors possess substantially greater financial resources and expertise in research, development, manufacturing, and clinical trials. AffaMed is identified as a competitor in company filings.
With modest revenue growth of 0.81 % within Overall company, Ocular Therapeutix Inc failed to increase sales with the same pace, like most of company's peers within this division. << More on OCUL Market Share.
*Market share is calculated based on total revenue.
August 7, 2024
In a significant development for the field of ocular therapeutics, Ocular Therapeutix has received positive feedback from the U.S. Food and Drug Administration (FDA) regarding its ongoing studies of AXPAXLI (also referred to as OTX- GPT) for the treatment of wet age-related macular degeneration (AMD). Specifically, the FDA has deemed the SOL-R trial suitable as a registrational study, setting the stage for the potential commercialization of this groundbreaking therapy if the trial outcomes meet efficacy and safety expectations. Understanding Wet AMD and Current Treatment LandscapeWet AMD is a leading cause of vision loss among older adults and is characterized by the growth of abnormal blood vessels beneath ...
Nektar Therapeutics operates under a business model focused on developing and commercializing innovative medicines. The company's approach involves utilizing its proprietary technology platforms to create novel therapeutic candidates and establish partnerships with pharmaceutical and biotechnology firms for clinical development and commercialization. Nektar Therapeutics aims to bring transformative therapies to market that address significant unmet medical needs.
Mineralys Therapeutics Inc is a biotechnology company that follows the business model of developing and commercializing novel therapeutics for various diseases. They focus on discovering and advancing small molecule drugs based on innovative research approaches. Their business model is centered around conducting preclinical and clinical trials, obtaining regulatory approvals, and ultimately bringing their therapeutic products to market for improved patient outcomes.
Legend Biotech Corporation is a biotech company focused on developing innovative cell therapies and gene therapies to address unmet medical needs in various diseases.
Kiora Pharmaceuticals Inc operates with a business model focused on the research, development, and commercialization of innovative pharmaceutical products for various medical conditions and diseases. The company aims to create value through the discovery of new drugs, rigorous clinical trials, and strategic partnerships for ultimate patient benefit and sustainable growth.
Sources:
Ocular Therapeutix Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Ocular Therapeutix Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
